This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Senti, M. Articles by Vidal-Barraquer, F. Search for Related Content PubMed PubMed Citation Articles by Senti, M. Articles by Vidal-Barraquer, F.

Circulation, Vol 85, 30-36, Copyright © 1992 by American Heart Association

ARTICLES

Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes

M Senti, X Nogues, J Pedro-Botet, J Rubies-Prat and F Vidal-Barraquer
Department of Medicine, Hospital del Mar, Universidad Autonoma de Barcelona, Spain.

BACKGROUND. The role of lipoprotein disturbances in the development of peripheral vascular disease (PVD) has not been sufficiently clarified. METHODS AND RESULTS. The relations among concentrations of intermediate density lipoproteins (IDL), apoprotein (apo) B, apo E, and other lipoproteins were studied in 102 men with PVD and 100 healthy men who formed the control group. Patients with PVD had significantly higher levels of serum triglycerides, very low density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL proteins, IDL cholesterol, and IDL triglycerides and lower levels of high density lipoproteins (HDL) than controls. Serum cholesterol and triglycerides were normal in 30 patients (cholesterol, less than 5.2 mmol/l; triglycerides, less than 2.3 mmol/l), who had significant increases in IDL triglycerides and significant decreases in HDL cholesterol compared with the 47 controls, who had normal cholesterol and triglyceride levels. Patients with more severe distal involvement showed higher cholesterol and triglycerides carried by IDL and a greater reduction in HDL cholesterol. Smoking patients with PVD showed increased VLDL cholesterol and VLDL triglycerides and lower HDL concentrations. Apo E polymorphism in our study population does not differ from that reported for other European populations. Alleles epsilon 2 and epsilon 4 had a major impact on serum triglycerides and VLDL lipids in our patients with PVD. CONCLUSIONS. Lipoprotein disturbances are a major risk factor for PVD. IDL abnormalities play an important role in the development and severity of PVD and should also be considered a vascular risk factor in normocholesterolemic and normotriglyceridemic patients.

This article has been cited by other articles:

				J. J. Carrero, E. Lopez-Huertas, L. M. Salmeron, L. Baro, and E. Ros Daily Supplementation with (n-3) PUFAs, Oleic Acid, Folic Acid, and Vitamins B-6 and E Increases Pain-Free Walking Distance and Improves Risk Factors in Men with Peripheral Vascular Disease J. Nutr., June 1, 2005; 135(6): 1393 - 1399. [Abstract] [Full Text] [PDF]

				G. Kolovou, D. Daskalova, and D. P. Mikhailidis Apolipoprotein E Polymorphism and Atherosclerosis Angiology, January 1, 2003; 54(1): 59 - 71. [Abstract] [PDF]

				R. J. Valentine, R. Verstraete, G. P. Clagett, and J. C. Cohen Premature Cardiovascular Disease Is Common in Relatives of Patients With Premature Peripheral Atherosclerosis Arch Intern Med, May 8, 2000; 160(9): 1343 - 1348. [Abstract] [Full Text] [PDF]

				C Aubo, M Senti, J Marrugat, M Tomas, J Vila, J Sala, and R Masia Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus Eur. Heart J., January 1, 2000; 21(1): 33 - 38. [Abstract] [PDF]

				I. Tkac, B. P. Kimball, G. Lewis, K. Uffelman, and G. Steiner The Severity of Coronary Atherosclerosis in Type 2 Diabetes Mellitus Is Related to the Number of Circulating Triglyceride-Rich Lipoprotein Particles Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3633 - 3638. [Abstract] [Full Text]

				E. Stroes, T. de Bruin, H. de Valk, W. Erkelens, J.-D. Banga, H. van Rijn, H. Koomans, and T. Rabelink NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants Cardiovasc Res, December 1, 1997; 36(3): 445 - 452. [Abstract] [Full Text] [PDF]

				M. Catalano, E. Perilli, G. Carzaniga, G. Scandale, and M. Carotta Arterial Damage, Triglycerides, Apolipoprotein, and Lp-(a) Values in PVD Patients Clinical and Applied Thrombosis/Hemostasis, April 1, 1997; 3(2): 104 - 109. [Abstract] [PDF]

				V. Hachinski, C. Graffagnino, M. Beaudry, G. Bernier, C. Buck, A. Donner, J. D. Spence, G. Doig, and B. M. J. Wolfe Lipids and Stroke: A Paradox Resolved Arch Neurol, April 1, 1996; 53(4): 303 - 308. [Abstract] [PDF]

				M. Senti, J. Pedro-Botet, J. Rubies-Prat, and F. Vidal-Barraquer Secondary Prevention of Coronary Heart Disease in Patients with Extracoronary Atherosclerosis: A Need for Accuracy of Low Density Lipoprotein Determination Angiology, March 1, 1996; 47(3): 241 - 246. [Abstract] [PDF]

				C. Alessandri, S. Basili, M. Maurelli, P. Andreozzi, A. Colletta, M. Paradiso, and C. Cordova Apolipoproteins C-II and C-III in Peripheral Arterial Disease Angiology, February 1, 1994; 45(2): 131 - 136. [Abstract] [PDF]